
    
      The experimental aspects of this experimental plan will include:

        1. Subjects will first be treated with Mannitol prior to chemotherapy infusion (Mannitol
           20%; delivered IA, 12.5 mL over 2 minutes) in order to disrupt the blood brain barrier.
           This technique has been used in several thousand subjects in previous studies for the IA
           delivery of chemotherapy for malignant glioma.

        2. Subjects will then be treated with repeated intraarterial delivery (SIACI) of
           Bevacizumab. Each subject will receive one dose of IA Bevacizumab on day 30, followed by
           chemoradiation. SIACI of Bevacizumab will be repeated every three months for a total of
           3 infusions.
    
  